Home / Market News / $PPC

$PPC news and market catalysts

The 13 most recent market catalysts affecting $PPC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

13 catalysts 4 high impact 6 bullish 3 bearish Food Products
Nov 18, 2026 Corporate Catalyst Bullish Impact 55
UBS Adjusts Price Target on Pilgrim's Pride to $31 From $28, Maintains Neutral Rating
UBS adjusted its price target for Pilgrim's Pride, increasing it from $28 to $31. This upward revision suggests that UBS analysts see slightly more upside potential in the company'…
Nov 12, 2026 Corporate Catalyst Bearish Impact 95
Presidio Production Company Reports Third Quarter 2026 Financial Results
Presidio Production Company announced its third-quarter 2026 financial results, revealing a substantial earnings per share (EPS) miss of $(1.80) compared to the consensus estimate …
Nov 11, 2026 Corporate Catalyst Neutral Impact 55
UK Competition Watchdog Invites Comments on Pilgrim's Pride Corp. Takeover of Walkers Deli & Sausage Co.
The filing indicates that the UK Competition and Markets Authority (CMA) is seeking public input on Pilgrim's Pride Corporation's acquisition of Walkers Deli & Sausage Co. This is …
Nov 5, 2026 Corporate Catalyst Bullish Impact 55
The Precision Peptide Company Moves Early on New Federal Peptide Policy, Adding All Six Covered Peptides to Its Prescription Platform
The Precision Peptide Company is proactively integrating a new federal HHS policy by adding six previously unavailable peptides to its U.S. prescription platform. This move is sign…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Propanc Biopharma Advances Bioanalytical and Immunogenicity Assay Development for Phase 1b Study
Propanc Biopharma announced it is advancing bioanalytical and immunogenicity assay development for its lead clinical candidate, PPC-001, in preparation for a Phase 1b study. This d…
Oct 29, 2026 Corporate Catalyst Bullish Impact 65
The Precision Peptide Company Inc. Quadruples U.S. Telehealth Formulary
The Precision Peptide Company Inc. announced a substantial expansion of its U.S. telehealth formulary, increasing its offerings from four to 16 prescription therapies across seven …
Oct 22, 2026 Corporate Catalyst Bullish Impact 65
The Precision Peptide Company Secures Exclusive Manufacturing Rights for Needle-Free Product Line
The Precision Peptide Company has announced it secured exclusive manufacturing rights for its entire line of needle-free peptide therapies, including transdermal patches and oral s…
Oct 14, 2026 Corporate Catalyst Bullish Impact 75
Propanc Biopharma Says Published Pilot Study Showed 85.9% Mean Tumor Weight Reduction With PRP In Pancreatic Cancer Animal Model
This news is a significant corporate catalyst for Propanc Biopharma (PPC) due to the highly positive preclinical data in a challenging disease area like pancreatic cancer. An 85.9%…
Oct 9, 2026 Corporate Catalyst Neutral Impact 95
Pilgrim’s Pride Forms Special Committee Of Independent, Disinterested Directors To Mull Aug. 18 Proposal From JBS
Pilgrim's Pride (PPC) has established a special committee to review an unsolicited acquisition proposal from JBS. This is a significant development as it indicates the board is ser…
Aug 20, 2026 Corporate Catalyst Neutral Impact 95
Pilgrim's Pride Confirms That JBS Made Offer To Acquire Company; Will Form Special Committee To Evaluate The Proposal
JBS, the majority shareholder of Pilgrim's Pride, has made an unsolicited offer to acquire the remaining shares of PPC. This is a significant corporate catalyst as it could lead to…
Aug 17, 2026 Corporate Catalyst Neutral Impact 75
Pilgrim's Pride's Pilgrim's Europe Announces Deal To Acquire Walkers Deli & Sausage From Samworth Brothers; Terms Not Disclosed
Pilgrim's Pride's acquisition of Walkers Deli & Sausage is a strategic move to strengthen its position in the European prepared foods market, particularly in the UK. This could lea…
Aug 7, 2026 Corporate Catalyst Bearish Impact 55
UBS Maintains Neutral on Pilgrims Pride, Lowers Price Target to $28
UBS analyst Matheus Enfeldt maintained a 'Neutral' rating on Pilgrims Pride (PPC) but lowered the price target from $30 to $28. This action indicates that while the analyst doesn't…
Jul 29, 2026 Corporate Catalyst Bearish Impact 92
Pilgrims Pride Q2 Adj. EPS $0.64 Misses $0.69 Estimate, Sales $4.626B Miss $4.710B Estimate
Pilgrims Pride (PPC) announced Q2 adjusted EPS of $0.64, missing the $0.69 estimate by 7.25%, and sales of $4.626 billion, missing the $4.710 billion estimate by 1.78%. This repres…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.